Tyra Biosciences (TYRA) Stock Forecast, Price Target & Predictions
TYRA Stock Forecast
Tyra Biosciences stock forecast is as follows: an average price target of $30.50 (represents a 85.75% upside from TYRA’s last price of $16.42) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
TYRA Price Target
TYRA Analyst Ratings
Tyra Biosciences Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 18, 2024 | Jason Zemansky | Bank of America Securities | $31.00 | $25.98 | 19.32% | 88.79% |
Sep 19, 2024 | Matt Biegler | Oppenheimer | $33.00 | $24.64 | 33.90% | 100.97% |
Aug 15, 2024 | Christopher Raymond | Raymond James | $33.00 | $21.57 | 52.99% | 100.97% |
Aug 08, 2024 | Mitchell Kapoor | H.C. Wainwright | $25.00 | $19.50 | 28.21% | 52.25% |
Mar 20, 2024 | Mitchell Kapoor | H.C. Wainwright | $23.00 | $17.37 | 32.41% | 40.07% |
Feb 03, 2023 | - | Oppenheimer | $17.00 | $13.30 | 27.82% | 3.53% |
Tyra Biosciences Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 4 | 5 |
Avg Price Target | $31.00 | $30.50 | $29.00 |
Last Closing Price | $16.42 | $16.42 | $16.42 |
Upside/Downside | 88.79% | 85.75% | 76.61% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 18, 2024 | Bank of America Securities | - | Buy | Upgrade |
Oct 11, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Oct 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 19, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Aug 15, 2024 | Piper Sandler | - | Overweight | Initialise |
Aug 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jul 08, 2024 | Cowen & Co. | Buy | Buy | Hold |
Jul 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
May 10, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Feb 03, 2023 | Oppenheimer | - | Outperform | Initialise |
Tyra Biosciences Financial Forecast
Tyra Biosciences Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Tyra Biosciences EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Tyra Biosciences Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-27.90M | $-25.54M | $-24.55M | $-25.45M | $-30.92M | $-28.53M | $-28.10M | $-26.10M | $-27.00M | $-23.39M | $-23.96M |
High Forecast | $-27.90M | $-25.54M | $-24.55M | $-25.45M | $-30.92M | $-28.53M | $-28.10M | $-26.10M | $-27.00M | $-20.47M | $-23.96M |
Low Forecast | $-27.90M | $-25.54M | $-24.55M | $-25.45M | $-30.92M | $-28.53M | $-28.10M | $-26.10M | $-27.00M | $-26.32M | $-23.96M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Tyra Biosciences SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Tyra Biosciences EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.48 | $-0.44 | $-0.42 | $-0.43 | $-0.53 | $-0.49 | $-0.48 | $-0.44 | $-0.46 | $-0.40 | $-0.41 |
High Forecast | $-0.48 | $-0.44 | $-0.42 | $-0.43 | $-0.53 | $-0.49 | $-0.48 | $-0.44 | $-0.46 | $-0.35 | $-0.41 |
Low Forecast | $-0.48 | $-0.44 | $-0.42 | $-0.43 | $-0.53 | $-0.49 | $-0.48 | $-0.44 | $-0.46 | $-0.45 | $-0.41 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - |
Tyra Biosciences Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
RAPT | RAPT Therapeutics | $2.27 | $42.20 | 1759.03% | Hold |
IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
HOWL | Werewolf Therapeutics | $2.26 | $12.00 | 430.97% | Buy |
XLO | Xilio Therapeutics | $1.44 | $7.00 | 386.11% | Buy |
MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
TYRA | Tyra Biosciences | $16.42 | $30.50 | 85.75% | Buy |
DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
CNTB | Connect Biopharma | $1.20 | $1.50 | 25.00% | Buy |
IKNA | Ikena Oncology | $1.72 | $1.33 | -22.67% | Buy |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
TYRA Forecast FAQ
Is Tyra Biosciences a good buy?
Yes, according to 5 Wall Street analysts, Tyra Biosciences (TYRA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of TYRA's total ratings.
What is TYRA's price target?
Tyra Biosciences (TYRA) average price target is $30.5 with a range of $25 to $33, implying a 85.75% from its last price of $16.42. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Tyra Biosciences stock go up soon?
According to Wall Street analysts' prediction for TYRA stock, the company can go up by 85.75% (from the last price of $16.42 to the average price target of $30.5), up by 100.97% based on the highest stock price target, and up by 52.25% based on the lowest stock price target.
Can Tyra Biosciences stock reach $20?
TYRA's average twelve months analyst stock price target of $30.5 supports the claim that Tyra Biosciences can reach $20 in the near future.
What is Tyra Biosciences's current price target trend?
1 Wall Street analyst forecast a $31 price target for Tyra Biosciences (TYRA) this month, up 88.79% from its last price of $16.42. Compared to the last 3 and 12 months, the average price target increased by 85.75% and increased by 76.61%, respectively.
What are Tyra Biosciences's analysts' financial forecasts?
Tyra Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-114M (high $-114M, low $-114M), average SG&A $0 (high $0, low $0), and average EPS is $-1.937 (high $-1.937, low $-1.937). TYRA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-103M (high $-103M, low $-103M), average SG&A $0 (high $0, low $0), and average EPS is $-1.763 (high $-1.763, low $-1.763).